RECLUDIX

Recludix is employing this platform approach first in the development of SH2 domain inhibitors for the treatment of inflammatory disease and cancer. SH2 domains have been recognized as playing a key role in disease signaling pathways for over 30 years; however, scientists had been unable to target them for the development of therapeutics. Recludix has developed a novel SH2-focused platform that integrates new chemical approaches and technologies, including custom SH2 domain libraries and assays, to develop precision small molecule medicines... At Recludix, we are innovators and inventors. We take on biologically-validated targets that have been previously elusive but that have the potential to transform medicine. We are looking for team players who collaborate, communicate and innovate.

Also known as: Recludix Pharma, Recludix Pharma, Inc.

Primary location: San Diego United States